Mittwoch, 27.05.2026 | 08.45 – 20.00 Uhr | Radisson Blu Frankfurt & ONLINE
SKY AF Summit Frankfurt – Innovationen in der AF-Therapie
Der SKY AF Summit bringt führende internationale Experten aus Kardiologie, Elektrophysiologie und Herzchirurgie zusammen, um aktuelle Entwicklungen und Innovationen in der Behandlung von Vorhofflimmern zu diskutieren. Die Veranstaltung beleuchtet neue therapeutische Strategien, moderne Ablationsverfahren sowie aktuelle Studien zur Schlaganfallprävention und zur Behandlung komplexer AF-Patienten.
Mit 4 CME-Punkten zertifiziert
Programm
27.05.2026
Scientific Program Directors
Prof. Dr. Reza Wakili
Universitätsklinikum Frankfurt
Prof. Dr. Dobromir Dobrev
Universitätsklinikum Duisburg-Essen
08.00 – 08.45 am Check-In
08.00 – 08.45 am Welcome and introduction
Prof. Dr. Reza Wakili & Prof. Dr. Dobromir Dobrev
09.00 – 10.20 am
Translational Insights into AF Mechanisms
Translational Insights into AF Mechanisms
Chair
Prof. Dr. Dobromir Dobrev | Prof. Dr. Dominik Linz
Panel Discussion
Prof. Dr. Joachim Ehrlich | Prof. Dr. Christian Ukena
09.00 am
Role of Atrial Cardiomyocyte Inflammatory Signaling
Prof. Dr. Dobromir Dobrev
Universitätsmedizin Essen
09.20 am
Genetics – Lessons Learned and Current Implications
Prof. Dr. Stefan Kääb
LMU Klinikum
09.35 am
Role of Large Animal Models and In-Vitro Experiments
Prof. Dr. Constanze Schmidt
Universitätsmedizin Göttingen
09.50 am
Role of Mitochondrial Dysbalance
Prof. Dr. Niels Voigt
Universitätsmedizin Göttingen
10.05 am
AF & HFreEF – Translationale View on Mechanisms and Therapy
Dr. Andreas Böhmer
Universitätsmedizin Frankfurt
10.20– 11.30 am
Stroke Prevention in AF – Part I
Chair
Prof. Dr. Thorsten Lewalter | Prof. Dr. Reza Wakili
Panel Discussion
Prof. Dr. Lars Eckardt | PD Dr. Verena Tscholl | Prof. Dr. Christian Ukena
10.20 am
Oral Anticoagulation in 2026 – Real-World Perspectives on Factor Xa & XI Inhibitors
PD Dr. Julia Erath-Honold
Universitätsmedizin Frankfurt
10.34 am
Role of AHREs – Who Benefits Most From Oral Anticoagulation?
Prof. Dr. Paulus Kirchhof
Universitätsklinikum Hamburg-Eppendorf
10.49 am
Oral Anticoagulation After Successful PVI – Still Required?
Prof. Dr. Andreas Metzner
Universitätsklinikum Hamburg-Eppendorf
11.02 am
Epidemiology of AF – what do we know, what do we need to know?
Prof. Dr. Renate Bonin-Schnabel
Universitätsklinikum Hamburg-Eppendorf
11.17
POAF – Insights Into the Role of New-Onset Atrial Fibrillation after CABG?
PD Dr. Florian Herrmann
LMU Klinikum
11.30 – 11.55 am Coffee Break and Industry Exchange
11.55 am – 01.00 pm
Novel Drug Therapies in AF Beyond OAC and PVI
Chair
Prof. Dr. Paulus Kirchhof | Prof. Dr. Constanze Schmidt
Panel Discussion
Prof. Dr. Dobromir Dobrev | Prof. Dr. Joachim Ehrlich | Prof. Dr. Niels Voigt
11.55 am
Role of Novel Antiarrhythmic Drugs
Prof. Dr. José Luis Merino Llorens
La Paz University Hospital, Madrid/Spain
12.10 pm
Role of Traditional Antiarrhythmic Drugs
Prof. Dr. Lars Eckardt
Universitätsklinikum Münster
12.25 pm
Comorbidies Metabolic Syndrom and Chronic-Kidney-Disease – Role of SGLT2-I, MRA, GLP1-A
Dr. Victoria Johnson
Universitätsmedizin Frankfurt
12.45 pm
AF Therapy in HOCM and Amyloidosis
PD Dr. Maria Papathanasiou
Universitätsmedizin Frankfurt
01.00 – 01.45 am Lunch Break and Industry Exchange
01.45 – 03.00 pm
Stroke Prevention in AF – Part II
Chair
Prof. Dr. Reza Wakili | Prof. Dr. Arian Sultan
Panel Discussion
Prof. Dr. Lars Eckardt | Prof. Dr. Jeff S. Healey | PD Dr. Verena Tscholl
01.45 pm
LAAO – Closure AF
Dr. Sebastian Haberkorn
Universitätsmedizin Frankfurt
02.00 pm
CHAMPION
Prof. Dr. Reza Wakili
Universitätsmedizin Frankfurt
02.15 pm
Outlook 2027 – LAAOS IV and What Else Is Coming and Needed
Prof. Dr. Jeff S. Healey
McMaster University, Hamilton/Kanada
02.30 pm
OPTION Trial
Prof. Dr. Thorsten Lewalter
Osypka Herzzentrum München
02.45 pm
Optimal Choice and Regime of Anticoagulation After LAAO
Prof. Dr. Boris Schmidt
MVZ CCB Frankfurt und Main-Taunus
03.00 – 04.15 pm
Surgery Meets Cardiology in AF Treatment
Chair
Prof. Dr. David M. Leistner | Prof. Dr. Thomas Walther
Panel Discussion
Prof. Dr. Armin Luik | PD Dr. Philipp Seppelt | Prof. Dr. Daniel Steven
03.00 pm
Epicardial PVI + LAAO – The Surgeon’s View
Prof. Dr. Nicolas Doll
Schüchtermann-Klinik Bad Rothenfelde
03.15 pm
Endocardial PVI + LAAO – The Electrophysiologist’s View
Prof. Dr. Arian Sultan
Asklepios Kliniken Hamburg
03.30 pm
Mitral Valve Repair Combined With PVI and LAAO
Dr. Fabian Emrich
Universitätsmedizin Frankfurt
03.45 pm
PVI ± LAAO After mTEER
Prof. Dr. Daniel Steven
Uniklinik Köln
04.00 pm
LIAB: PFA-PVI + LAAO (FARAWAVE + WATCHMAN With VersaCross)
Prof. Dr. Reza Wakili & Dr. Sebastian Haberkorn
Universitätsmedizin Frankfurt
04.15 – 04.40 pm Coffee Break and Industry Exchange
04.40 – 05.40 pm
Mapping and Ablation With PFA
Chair
Prof. Dr. Philipp Sommer | Prof. Dr. Reza Wakili
Panel Discussion
Prof. Dr. Armin Luik | PD Dr. Obaida Rana | Prof. Dr. Christian Sohns
04.40 pm
Focal PFA – For Which Arrhythmia?
PD Dr. Obaida Rana
Universitätsklinikum Düsseldorf
04.55 pm
PVI+ With PFA-Integrated 3D Mapping – Overview
Prof. Dr. Philipp Sommer
Herz- und Diabeteszentrum Nordrhein-Westfalen
05.10 pm
LIAB: PVI „+“ PFA Single-Shot integrated in 3D Mapping
Dr. Anastasia Falagkari
Universitätsmedizin Frankfurt
05.25 pm
LIAB: AFFERA – Re-Do Ablation With Sphere-9 & PVI-only With Sphere-360
PD Dr. Laura Rottner
Universitätsmedizin Frankfurt
05.40 – 06.50 pm
PVI in HFrEF, HFmrEF, HFpEF – Or All HFpAF?
Chair
Prof. Dr. Nassir F. Marrouche | Prof. Dr. Daniel Steven
Panel Discussion
PD Dr. Melanie Gunawardene | Prof. Dr. Thorsten Lewalter | PD Dr. Laura Rottner
05.40 pm
HFrEF
Prof. Dr. Christian Sohns
Herz- und Diabeteszentrum Nordrhein-Westfalen
05.55 pm
HFpEF
PD Dr. Abdul Shokor Parwani
Deutsches Herzzentrum der Charité (DHZC)
06.10 pm
HFxEF – What Trials are Required for the Future?
Prof. Dr. Nassir F. Marrouche
Tulane University Heart & Vascular Institute, New
06.20 pm
HOCM and Amyloidosis: Role of Single Shot PFA-PVI
Prof. Dr. Patrick Lugenbiel
Universitätsklinikum Heidelberg
06.35 pm
Role of AF Burden vs. Freedom From AF in HF&AF
Prof. Dr. Jason G. Andrade *remote*
The University of British Columbia, Vancouver/Kanada
06.50 – 07.00 pm Summary
Prof. Dr. Reza Wakili & Prof. Dr. Dobromir Dobrev
07.00 – 08.00 pm Meet the Experts in the Speakers‘ Corner
Sponsoren
AstraZeneca GmbH
EUR 2.000
BIOTRONIK SE & Co. KGEUR 1.500
Bristol-Myers Squibb GmbH & Co. KGaAEUR 3.000
Daiichi Sankyo Deutschland GmbHEUR 2.000
Edwards Lifesciences GmbHEUR 1.500
Lilly Deutschland GmbHEUR 1.000
Novartis Pharma GmbHEUR 1.000
Novo Nordisk Pharma GmbHEUR 1.000
Sanofi-Aventis Deutschland GmbHEUR 1.000
